Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases

Asher Bio Appoints Independent Director Elaine Sun to its Board

Fulcrum Therapeutics Provides Business Update and 2023 Outlook